Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tonix Pharm Holdings (NQ: TNXP )

0.2405 +0.0116 (+5.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 51,108,824
Open 0.2447
Bid (Size) 0.2815 (250)
Ask (Size) 0.2860 (4)
Prev. Close 0.2289
Today's Range 0.2217 - 0.2476
52wk Range 0.1180 - 22.14
Shares Outstanding 186,894,225
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
How Is The Market Feeling About Tonix Pharmaceuticals?
Via Benzinga
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers
Via ACCESSWIRE

Performance

YTD
-98.20%
-98.20%
1 Month
+70.33%
+70.33%
3 Month
+53.38%
+53.38%
6 Month
-79.09%
-79.09%
1 Year
-98.53%
-98.53%

More News

Read More
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awaits FDA Decision on New Fibromyalgia Treatment
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands Leadership Team to Support TNX-102 SL Launch
Via Investor Brand Network
Exposures Product Safety
InvestorkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) COO to Present at NobleCon20 Emerging Growth Conference
Via Investor Brand Network
Exposures Product Safety
Looking Into Tonix Pharmaceuticals's Recent Short Interest
Via Benzinga
(TNXP) - Analyzing Tonix Pharmaceuticals's Short Interest
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Keysight Technologies Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) COO to Present at Winter 2024 Investor Summit
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Phase 3 Success for TNX-102 SL in Fibromyalgia Treatment
Via Investor Brand Network
Exposures Product Safety
Jessica Edgar Morris, COO of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), to Present at NobleCon20
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Launches Rapid-Relief Migraine Treatments for Urgent Needs
Via Investor Brand Network
Exposures Product Safety
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments
Via ACCESSWIRE
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Publishes Promising Data on TNX-801 Vaccine for Mpox and Smallpox
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Submits NDA for Fibromyalgia Treatment and Advances Mpox Vaccine Development
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and Kenya Medical Research Institute Partner on Phase I Trial for Mpox and Smallpox Vaccine TNX-801
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Promising Mpox Vaccine Data at World Vaccine Congress
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at BIO-Europe in Stockholm
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at ThinkEquity Conference
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present Mpox Vaccine Research at World Vaccine Congress Europe 2024
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Receives First Payment from U.S. Defense Agency to Develop Broad-Spectrum Antiviral Agents
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Submits New Drug Application to FDA for TNX-102 SL for Fibromyalgia Treatment
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), X-Chem to Collaborate in Development of Broad-Spectrum Antivirals
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Why Tonix Pharmaceuticals (TNXP) Stock Is Moving
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.